Armata Pharmaceuticals Inc. Common Stock (ARMP)

About ARMP

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . Th…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

61

Website

www.armatapharma.com/

Fundamentals

1-day range

$4.99$5.45

Market cap

$185.39M

P/E (trailing)

—

P/E (forward)

-3.42

EPS (trailing)

$-7.76

Dividend yield

—

Beta

1.40

Avg. volume

154.0K

Dividend pay date

May 10, 2019

Forecasts

2 analyst ratings

Armata Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ARMP

  Armata Pharmaceuticals Inc. Common Stock

  $5.24

  ▼ 3.50%
  Market cap $185.39MP/E —
  $2.4$16.34
• VYGR

  Voyager Therapeutics Inc. Common Stock

  $3.54

  ▲ 2.17%
  Market cap $181.26MP/E —
  $2.94$5.55
• TNYA

  Tenaya Therapeutics Inc. Common Stock

  $0.691

  ▼ 0.58%
  Market cap $158.19MP/E —
  $0.532$2.35
• LENZ

  LENZ Therapeutics Inc. Common Stock

  $5.12

  ▲ 6.34%
  Market cap $156.62MP/E —
  $4.54$50.4
• HUMA

  Humacyte Inc. Common Stock

  $0.6538

  ▼ 5.66%
  Market cap $153.04MP/E —
  $0.5261$2.55
• CRBU

  Caribou Biosciences Inc. Common Stock

  $1.62

  ▼ 2.41%
  Market cap $148.77MP/E —
  $1.38$3.54
• TARA

  Protara Therapeutics Inc. Common Stock

  $3.82

  ▼ 4.26%
  Market cap $223.13MP/E —
  $3.02$7.82

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Bronchiectasis Market is Expected to Surge at a CAGR of 15% by 2036, Owing to the Launch of DPP1/CatC Inhibitors, Therapeutic Phage Cocktails, Nebulized Mucoactive Agents, and Other Novel Mechanisms | DelveInsight
  Yahoo · 8/13/2026
• Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate
  benzinga · 8/12/2026
• Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
  Yahoo · 8/12/2026
• Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate
  Benzinga · 8/12/2026
• Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic
  SeekingAlpha · 8/6/2026

• Deborah Birx · July 10, 2026 · Tax Withholding

  14.0K @ $4.26
• Gilmer Daniel B. · April 24, 2026 · Grant

  51.3K
• Pierre Kyme · March 14, 2026 · Tax Withholding

  1.0K @ $10.54
• Deborah Birx · March 14, 2026 · Tax Withholding

  4.9K @ $10.54
• House David Duane · March 9, 2026 · Grant

  109.9K
• Pierre Kyme · March 9, 2026 · Grant

  183.1K
• Deborah Birx · March 9, 2026 · Grant

  421.2K
• Peterson Todd C. · March 9, 2026 · Grant

  25.6K
• Robin Kramer · March 9, 2026 · Grant

  25.6K
• Sarah J. Schlesinger · March 9, 2026 · Grant

  25.6K
• Kostas D. Odysseas · March 9, 2026 · Grant

  25.6K
• Jules Haimovitz · March 9, 2026 · Grant

  25.6K
• PATTI JOSEPH M · March 9, 2026 · Grant

  25.6K

Institutional Ownership

March 31, 2026

Total shares held

3.86M

Total value held

$39.37M

Institutional holders

43